Medpace Holdings Inc vs Progressive Corp — how do they compare? Medpace Holdings Inc trades at $602.38 (market cap $16.90B), while Progressive Corp trades at $208.32 (market cap $123.45B). The key difference: Progressive Corp is far larger — about 7.3× Medpace Holdings Inc's market cap, and Progressive Corp pays a 6.55% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PGR | |
|---|---|---|
Market Cap | $16.90B | $123.45B |
Sector | Technology | Financials |
52-Week High | $620.59 | $252.68 |
52-Week Low | $393.42 | $190.40 |
Enterprise Value | $16.52B | $131.66B |
Dividend Yield | — | 6.55% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.
PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →